Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Follicular 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Non-Hodgkin 10Lymphoma 10Lymphoma, Mantle-Cell 7Recurrence 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Neoplasms 4Leukemia, B-Cell 3Neoplasm, Residual 2Burkitt Lymphoma 2Mature B-Cell Malignancies 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Leukemia 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 3acalabrutinib 2Rituximab 2pembrolizumab 1obinutuzumab 1ibrutinib 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Vincristine 1Tacrolimus 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Mycophenolic Acid 1Mesna 1Melphalan 1Doxorubicin 1CA-4948 1Busulfan 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Diseases × obinutuzumab × 90 days × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡